Introduction
Factor VIII (FVIII) replacement therapy in patients with hemophilia A results, in up to 25% of the cases, in the development of anti-FVIII alloantibodies that inhibit FVIII procoagulant activity. The development of FVIII inhibitors precludes further therapeutic use of FVIII and remains a major therapeutic challenge. It has been documented that FVIII-specific CD4 + T lymphocytes are involved in the initiation of the humoral immune response to exogenous FVIII. 1, 2 In view of their capacity to stimulate naïve T cells, dendritic cells (DC) play a central role in initiation of the primary immune response. 3 Thus, in the context of a primary alloimmunization against FVIII, i.e. when FVIII-specific B lymphocytes are not yet present to internalize FVIII from the circulation and serve as antigen-presenting cells (APC), DC are the major cell type that activate specific CD4 + T lymphocytes. The low density lipoprotein (LDL) receptor-related protein (LRP), also known as the ␣2-macroglobulin receptor or CD91, is a member of the LDL receptor family of endocytic receptors that mediates the binding of multiple ligands and their transport from the cell surface to the endosomal compartment.
4 CD91/LRP expressed on transfected fibroblasts mediates at least 50% of FVIII uptake and degradation. 5, 6 FVIII catabolism by LRP is facilitated by heparan sulfate proteoglycans (HSPG).
7
Inactivation of the CD91 gene in conditional LRP-deficient mice confirmed the relevance of LRP for clearance of circulating FVIII. 8 The involvement of CD91 in FVIII uptake has been considered with respect to the half-life of therapeutically administered FVIII. CD91-targeted modulation of FVIII clearance has thus been proposed as an approach to prolong the efficiency of replacement treatments. However, its role in the internalization and processing of FVIII for presentation by APC is unknown.
Alloimmunization against exogenous FVIII represents the major hurdle of hemophilia treatment. We hypothesized that, in patients infused with FVIII, the CD91/LRP-dependent endocytic pathway plays an important role in FVIII uptake by professional APC, and is thus critical for the primary events leading to the anti-FVIII immune response. We, therefore, investigated the presence of functional CD91 at the surface of monocyte-derived human DC, and examined its capacity to mediate FVIII endocytosis and FVIII-specific T-cell activation.
Design and Methods

Proteins and antibodies
Methylamine-treated (activated) ␣-2-macroglobulinfluoroscein isothiocyanate (␣2M-FITC), CD91 and anti-CD91-FITC antibodies were purchased from Biomac (Leipzig, Germany). Receptor-associated protein (RAP) was obtained from Molecular Innovations, Inc. (Kordia Life Sciences, Leiden, The Netherlands).
Fluorescein conjugation of FVIII
Recombinant human FVIII (1000 IU, Kogenate SF, Bayer) was dialyzed against bicarbonate buffer (pH 9.2) containing 5 mM CaCl2 at 4°C for 2 h, followed by coupling with FITC for 7-8 h at 4°C. Unconjugated FITC was removed by dialyzing against RPMI-1640 media. The specific activity of FVIII-FITC was >4000 IU/mg, as assessed using a chromogenic assay (Dade-Behring), confirming the preservation of the structural and functional integrity of FVIII following FITC conjugation.
Radioactive conjugation of FVIII
Recombinant human FVIII (1000 IU, Kogenate SF, Bayer) was dialyzed against phosphate-buffered saline (PBS) at 4°C for 2 h. It was then labeled with 125 I to a specific activity of 915 cpm/fmole, using the iodogen method. Free iodine was removed by desalting on a PD-10 column equilibrated with X-VIVO 15 -2% bovine serum albumin (BSA).
Generation of dendritic cells
Monocytes from peripheral blood mononuclear cells (PBMC) were isolated by adherence from heparinized buffy coats of healthy donors or from blood samples from two patients with severe hemophilia A (aged 8 years and 14 years, both inhibitor-positive) in RPMI 1640-10% human AB serum, glutamine and antibiotics. Samples were obtained in accordance with the local ethical regulation. Adherent monocytes were cultured in X-VIVO
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-1% human AB serum, in the presence of 500 IU/10 6 cells, interleukin-4 (R&D Systems, Lille, France) and 1000 IU/10 6 cells granulocyte-monocyte colony-stimulating factor (ImmunoTools, Friesoythe, Germany). After 5 days of culture, the non-adherent DC-enriched fraction was harvested. The immature phenotype and CD91 expression of 5-day old DC were assessed by FACS using appropriate FITC and phycoerythin (PE)-labeled antibodies (Supplementary Figure 1) . DC were >90% pure. 
Labeling of dendritic cells by conjugated ligands
Labeling of mouse embryonic fibroblasts by FVIII-FITC
Mouse embryonic fibroblasts (MEF) were seeded at 2.2x10 4 cells/well onto flat-bottomed, 96-well plates and grown in DMEM containing 10% fetal calf serum (FCS) to 90% confluency. MEF, pre-incubated for 30 min in medium alone or with a 100 molar excess RAP, were incubated in 100 L medium containing 1% BSA with FVIII-FITC for 5 h at 37°C. The wells were gently washed with PBS and 50 L of water were added to each well and incubated for 30 min to lyse the cells. Fluorescence was then measured using a spectrofluorometer (TECAN, excitation at 492 nm and emission at 535 nm). Autofluorescence was subtracted.
Activation of a FVIII-specific T-cell clone
DC were generated from monocytes from a healthy donor (MHC haplotype: DRB1*1501/DRB5*01) in RPMI-1640 supplemented with 10% FCS. Five-day old DC were resuspended in DMEM:F12 (1:1) media containing 10% FCS and were distributed (10,000 cells/well) in 96-well round-bottomed, cell culture plates. DC were cultured with 5000 T cells (a human FVIII-specific CD4 + Tcell clone, D9E9) in DMEM:F12 (1:1) medium containing 10% FCS and 20 U/mL recombinant human interleukin-2 (Sigma), with FVIII (36 nM or 10 g/mL, 20 nM, 10 nM or 5 nM) or FVIII-FITC (2, 10 or 40 g/mL) for 20 h at 37°C. Production of interferon-␥ was measured in the supernatants using the human interferon-␥ Duo Set (DY285, R&D Systems). When indicated, DC were preincubated with a 100 molar excess of RAP for 30 min at 37°C. Controls included: T cells incubated alone, or T cells incubated with DC alone or in the presence of human recombinant factor IX (36 nM, Benefix, Baxter).
Results
Immature monocyte-derived DC express functional CD91
Five day-old immature DC revealed heterogeneous expression of CD91 ( Figure 1A ), which was high on 20.4±9.9% of CD11c + DC (ranging from 5.9 to 42.3; mean fluorescence intensity [MFI]: 251.1±109.1 in the case of 13 healthy donors). We explored the endocytic potential of CD91 on DC, using activated ␣2M as a model ligand for CD91. Labeling of DC with ␣2M-FITC was dose-dependent, with an optimal concentration of 100 g/mL of ␣2M following 2 h of incubation ( Figure 1B ). Labeling by ␣2M-FITC was dependent upon time and temperature ( Figure  1C ). Large ⌬MFI values between 37°C and 4°C (160.1 and <20 MFI for 10 g/mL ␣2M-FITC, respectively) demonstrate active endocytosis of ␣2M by DC. RAP is an inhibitor of receptors belonging to the family of LDL receptors, and is commonly used to substantiate CD91 as an endocytic receptor. 5, 6, 9 A 100 molar excess of RAP abrogated ␣2M endocytosis by DC ( Figure 1D ), thus confirming the involvement of CD91 in ␣2M internalization.
Internalization of FVIII by DC leads to the activation of FVIII-specific CD4 + T cells
The kinetics and molecular mechanisms underlying the endocytosis of FVIII by APC have not been described as yet. Internalization of FVIII by DC was studied using FITC-conjugated FVIII. We first confirmed that conjugation of FVIII with FITC does not alter the structure of FVIII; FITC-conjugation of FVIII did not modify the clotting factor's interaction with a series of monoclonal anti-FVIII antibodies ( Figure 2A ) or with von Willebrand factor; 10 CD91 bound to FVIII-FITC to a similar extent as to native FVIII, as assessed using an enzyme-linked immunosorbent assay ( Figure 2B) ; furthermore, the MEF cell line, which expresses surface CD91, was labeled by FVIII-FITC in a dose-dependent manner ( Figure 2C ).
Incubation of FVIII-FITC with DC resulted in a timeand dose-dependent increase of both labeling intensity and percentage of labeled cells at 37°C ( Figures 3A, 3B and data not shown). Optimal FVIII endocytosis occurred following 2 h of incubation. Confocal microscopy confirmed that FVIII was internalized by DC (data not shown). At 4°C, 40 g/mL FVIII resulted in baseline labeling of 25 to 35 MFI, which was stable between 15 Figure 3B ), thus suggesting saturation of the membrane-exposed receptors for FVIII after 15 min of incubation. We validated that FVIII endocytosis by DC resulted in presentation of FVIII-derived peptide to T lymphocytes. For this purpose, DC from MHC-matched donors were incubated with the human FVIII-specific CD4 + T-cell clone D9E9
11 in the presence of increasing amounts of FVIII. D9E9 was activated in a dose-dependent manner by FVIII-FITC, as assessed by the production of interferon-␥ in the culture supernatant ( Figure 3C ). Interferon-␥ was not detected when DC were incubated alone or when DC and D9E9 were incubated in the presence of an irrelevant antigen ( Figure 3D ). Importantly, DC loaded with FVIII and with FVIII-FITC activated D9E9 to a similar extent (Figure 3D) , further supporting the fact that FITC-conjugation does not alter endocytosis and endosomal processing of FVIII. 
The endocytosis of FVIII by DC is not mediated by CD91
We then investigated whether CD91 is implicated in FVIII endocytosis. Internalization of FVIII-FITC by MEF, which naturally express surface CD91, was inhibited by pre-incubation of the cells in the presence of a 100 molar excess of RAP (p<0.05), as previously reported ( Figure 4A ). 6 However, a 100 molar excess of RAP did not prevent the endocytosis of FVIII-FITC by DC, while it completely abrogated that of ␣2M ( Figure 4B ). Under similar conditions, RAP did not inhibit the endocytosis of FVIII-FITC by DC from two patients with severe hemophilia A (data not shown). A combination of RAP and heparinase III had no effect of FVIII-FITC uptake (data not shown). Because the lack of inhibitory effect of RAP on the uptake of FVIII-FITC could be related to the elevated FVIII concentrations used in our assays, we repeated the experiments with 20 nM iodine-conjugated FVIII, as described previously.
5 Labeling of DC from healthy donors with 125 I-FVIII was dose-dependent (data not shown). Pre-incubation of DC with a 50 or 100 molar excess of RAP or with 100 molar excess of anti-LRP antibodies did not prevent the uptake of 20 nM 125 I-FVIII ( Figure 4C ). Furthermore, activation of D9E9 by DC loaded with native unconjugated FVIII was not reduced when an excess of RAP was added to the co-culture for 20 h (Figure 4D) , confirming that the anti-endocytic role of RAP on FVIII, while significant to FVIII catabolism by non-immune cells, is negligible in the context of FVIII endocytosis by professional APC leading to activation of immune effectors.
Receptor-mediated endocytosis of antigens by DC involves both divalent ion-dependent and independent receptors. Co-incubation of DC with EDTA, which functionally blocks bivalent ion-dependent receptors such as CD91, abrogated ␣2M uptake, while it inhibited FVIII uptake by 70% (Figures 4B and 5) . It is known that EDTA mediates the dissociation of FVIII subunits.
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The inhibitory effect of EDTA was, however, not due to EDTA-induced FVIII dissociation, since dissociation of FVIII subunits requires a higher concentration of EDTA than that used in our assays (i.e., 5 mM), and a longer period of incubation. 
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Discussion
CD91/LRP is a catabolic receptor for FVIII. It is thus a plausible candidate as a specific receptor that mediates endocytosis of FVIII by APC, and may be involved in the elevated immunogenicity of therapeutically administered FVIII. In order to validate this hypothesis we used monocyte-derived DC as model APC, since DC represent the terminal stage of monocyte differentiation under physiological conditions both in vitro and in vivo.
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Here, we describe the kinetics of FVIII internalization by professional APC. APC internalize soluble antigens by different mechanisms, including receptor-mediated endocytosis, which requires only a few hours and, in most cases, is dependent on divalent ions. Incubation of FVIII with immature DC for 2h enabled a large majority of the cells to endocytose FVIII. In contrast, parallel control experiments performed with lucifer yellow, an established ligand for macropinocytosis, resulted in ligand endocytosis by only a marginal proportion of cells (data not shown). Furthermore, pre-incubation of the cells with 5 mM EDTA reduced FVIII uptake significantly, implying the involvement of a divalent ion-dependent endocytic pathway. Together with the dose-, time-and temperature-dependency of the endocytic process, our data are in favor of an active receptor-mediated internalization of FVIII. Importantly, we validated the functional presentation of FVIII-derived peptides on MHC II molecules to T lymphocytes.
CD91/LRP and other members of the LDL receptor family, such as VLDL, 16 have demonstrated affinity for FVIII in a RAP-sensitive manner. Expression of CD91 has been reported on various cell types including monocytes, macrophages and B lymphocytes. 17, 18 In our experiments, the surface expression of CD91/LRP on human DC was found to be 20% of the CD11c + DC population at a given time point, while 2h of incubation were sufficient for ␣2M to be internalized by more than 70% of the cells, resembling results of previous studies 19 and illustrating the elevated turn-over of CD91.
4 CD91/LRP, like various other endocytic receptors, is essentially located intracellularly and is in constant flux between intracellular storage and surface exposure. Interestingly, the expression of CD91 at the surface of immature DC was enhanced up to 2-fold following incubation of the cells in protein-free medium alone for 30 min prior to analysis by flow cytometry (data not shown), thus highlighting the probable contribution of serum proteins to LRP/CD91 internalization. Taken together, our data demonstrate the expression of CD91 on human immature DC and validate the CD91-dependent endocytic pathway in antigen uptake, as shown with ␣2M. Importantly, antigens endocytosed through CD91 are known to be presented to T lymphocytes in both an MHC I-and MHC II-restricted manner.
20,21
The importance of CD91/LRP to FVIII entry into professional APC and to the associated FVIII immunogenicity remains elusive. Our data demonstrate that endocytosis of FVIII by DC is not inhibited by RAP or by polyclonal anti-LRP IgG, irrespective of the detection method employed (i.e., FITC-or 125 I-conjugated FVIII) or the concentration of FVIII used. Cell surface HSPG have been shown to assist CD91/LRP in FVIII catabolism.
7 A combination of RAP and heparinase III, a specific inhibitor of HSPG, also failed to block FVIII endocytosis by DC at all time points tested (data not shown). Furthermore, RAP did not prevent DC from internalizing, processing and presenting FVIII to T lymphocytes. The absence of RAP-sensitivity on FVIII uptake by DC was unchanged in the absence or presence of molar excess of von Willebrand factor (data not shown).
The failure of CD91 and related receptors of the LDLreceptor family to play a dominant role in FVIII endocytosis by DC may be explained by several non-exclusive factors: CD91 is targeted by multiple ligands that compete with each other for binding to the receptor; 4 in the case of a large multivalent antigen such as FVIII, internalization may involve a series of alternative endocytic receptors specific for various glycoprotein moieties of the molecule ( Figure 5 ). Indeed, our recent results confirm the involvement of divalent ion-dependent mannose-sensitive receptors in the internalization of FVIII by monocyte-derived DC and subsequent presentation to CD4 + T lymphocytes. 22 Taken together, our results indicate that CD91 and other members of the LDL receptor family cannot be major therapeutic targets for reducing the immunogenicity of exogenous FVIII.
